← Bio Talent Intelligence

BANSEOG BIO TALENT INTELLIGENCE

Biotech · COMPANY INTELLIGENCE

ABL
BIO

We look for experience that translates one platform into multiple real development programs while using partner scale without giving away the capability the company needs to keep.

TALENT PATTERN · 01People who have moved the same platform into different real programs may become more scarce.
8 roles & capabilities observed5 business & hiring changes observed2 Talent Patterns published

TALENT PATTERNS

See which experience may become scarce first.

01PLATFORM-TO-PROGRAM

TALENT CAPABILITY

Platform-to-Program Translation

Platform Adaptation Builder

The capability to redesign the conditions and execution model around one platform so different targets, modalities and therapeutic programs can actually use it.

Understanding a platform is different from adapting the same principle into development-ready form across different programs.

Core capability
  • Platform Adaptation
  • Program Translation
  • Modality Reframing
  • Development Conversion
Experience that strengthens it
  • Discovery Research
  • Research Science
  • Translational Research
  • Tech Transfer

People who have moved the same platform into different real programs may become more scarce.

We look beyond platform familiarity to experience adapting the same technical principle to different targets, modalities and programs and carrying it into the next development stage.

Why nowABL Bio is applying the Grabody platform across multi-program collaborations with GSK and Lilly and continues to extend the platform into siRNA optimization and next-generation BBB shuttle work in 2026.

Company & HR

What did this person change—and what did they preserve—when moving the same platform into another program?

Who should we look at first?Discovery / Research Science / Translational depth plus platform adaptation, multi-program development or cross-modality translation experience
Where should we look?

Look beyond bispecific antibodies to BBB shuttle, antibody engineering, nucleic-acid delivery, translational platforms and ADC teams that have reused one technical base across programs.

What should we do next?

Do not stop at “platform experience.” Test how the candidate separated common platform logic from program-specific constraints and moved the work into a real next development stage.

Hiring playbook

Search rule

Look beyond years on a platform for evidence of what changed and what stayed constant when the technology moved across targets, modalities or programs.

Evidence to test in interview

Ask how common platform logic was separated from program-specific constraints and whether those decisions enabled the next development stage.

Build internally

Give strong platform scientists ownership of adaptation across modalities and targets, not only delivery inside one program.

Request analysis of this talent market →
View evidence7
Roles & capabilities
Discovery ResearchObserved again
Research ScienceObserved again
Translational ResearchObserved again
Tech TransferObserved again
Business changes
ABL Bio extends Grabody-B and expands next-generation platform work2026-05-08Source ↗
Lilly and ABL Bio form a multi-program Grabody collaboration2025-11-12Source ↗
GSK licenses Grabody-B for multiple targets and modalities2025-04-07Source ↗
02RETAINED-CAPABILITY

TALENT CAPABILITY

Retained Capability

Partner Boundary Architect

The capability to use external partner scale while deciding which technical knowledge, judgment and development responsibility must remain inside as reusable execution capability.

Working with a major partner is different from making the organization itself more capable after the collaboration.

Core capability
  • Decision Boundary
  • Retained Know-how
  • Development Ownership
  • Partner Handoff
Experience that strengthens it
  • Alliance Management
  • Global Business
  • Tech Transfer
  • CMC / Process Development

The important part of a major partnership may be what remains inside the company afterward.

We look beyond partner size to what technical knowledge, decision rights and development responsibility stay inside—and whether that retained capability strengthens the next program.

Why nowABL Bio is expanding global partnerships with companies including GSK and Lilly while also pursuing internalization of process-development and quality-control CMC functions through its Samsung-dong integration.

Company & HR

What can our organization do directly after the partnership that it could not do before?

Who should we look at first?Alliance / Global Business / Tech Transfer depth plus partner-boundary, retained know-how or internal-capability build experience
Where should we look?

Look across Licensing, Alliance and Scientific BD as well as CMC, Process Development and Tech Transfer for people who have designed the boundary between external scale and internal ownership.

What should we do next?

Look past the partner logo. Ask what was transferred, what stayed internal and how the retained capability changed execution in the next program.

Hiring playbook

Search rule

Look beyond partner names for what was transferred, what remained inside and how internal execution changed afterward.

Evidence to test in interview

Ask the candidate to separate shared rights and responsibilities from the judgment, know-how and execution capability the company retained.

Build internally

Add retained-capability and internal-development boundary ownership to Alliance and BD roles, not only relationship management.

Request analysis of this talent market →
View evidence7
Roles & capabilities
Alliance ManagementObserved again
Global BusinessObserved again
Tech TransferObserved again
CMC
Business changes
NEOK Bio leads U.S. clinical execution for ABL206 and ABL2092026-04-23Source ↗
Lilly and ABL Bio form a multi-program Grabody collaboration2025-11-12Source ↗
GSK licenses Grabody-B for multiple targets and modalities2025-04-07Source ↗

CURRENT EVIDENCE

Start with what is currently observed.

Current roles & capabilities

Discovery ResearchContinuing signalObserved again
Research ScienceContinuing signalObserved again
Translational ResearchContinuing signalObserved again
Alliance ManagementContinuing signalObserved again
Global BusinessContinuing signalObserved again
Tech TransferContinuing signalObserved again
CMCContinuing signal
Process DevelopmentContinuing signal
Repeatedly observed pressure

Discovery Research · Research Science · Translational Research · Alliance Management · Global Business · Tech Transfer

Business & hiring changes

2026-05-08 · Pipeline changeABL Bio extends Grabody-B and expands next-generation platform work

The company is pursuing additional licensing, siRNA optimization, next-generation BBB shuttle research and further bispecific ADC development.

Source ↗
2026-04-23 · Global expansionNEOK Bio leads U.S. clinical execution for ABL206 and ABL209

Two ABL-developed bispecific ADC programs are in U.S. Phase 1 with global development and commercialization led by NEOK Bio.

Source ↗
2025-11-12 · PartnershipLilly and ABL Bio form a multi-program Grabody collaboration

The agreement applies the Grabody platform across multiple therapeutic candidates, modalities and therapeutic areas.

Source ↗
2025-04-07 · PartnershipGSK licenses Grabody-B for multiple targets and modalities

The Grabody-B platform is applied across antibodies and nucleic-acid modalities in a multi-program global partnership.

Source ↗
2024-04-11 · Manufacturing changeABL Bio plans R&D consolidation and CMC internalization in Samsung-dong

The new headquarters is designed to consolidate dispersed teams, expand research infrastructure and internalize process-development and quality-control capability.

Source ↗
BANSEOG ANALYSISA proprietary platform is being converted into multiple development programs while internal execution depth and partner boundaries become more important

CURRENT TALENT MARKET

Then see the talent market moving around it.

TALENT & CAREER

How far can my experience transfer?

No evidence-backed adjacent career path is currently linked.

COMPANY & HR

Who else is looking at the same talent?

No evidence-backed talent-competitor relationship is currently linked.